Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kyowa Kirin Co. is conducting a Phase 1 clinical study titled ‘A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors.’ The study aims to assess the safety and tolerability of KK2269, both as a standalone treatment and in combination with docetaxel, for adults with advanced or metastatic solid tumors.
The interventions being tested are KK2269, an investigational drug administered intravenously, and docetaxel, a known antineoplastic drug. KK2269 is designed to treat solid tumors, either alone or alongside docetaxel, to determine optimal dosing strategies.
This interventional study is non-randomized and sequential, with no masking involved. Its primary purpose is treatment-focused, aiming to establish safe dosage levels for future studies.
The study began on February 5, 2024, with primary completion expected by January 7, 2025. These dates are crucial as they indicate the timeline for data collection and analysis, impacting future research and development phases.
The study’s progress could influence Kyowa Kirin’s stock performance by enhancing investor confidence in their oncology pipeline. Success in this trial may position the company favorably against competitors in the cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.